<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01108744</url>
  </required_header>
  <id_info>
    <org_study_id>2009P000313</org_study_id>
    <nct_id>NCT01108744</nct_id>
  </id_info>
  <brief_title>Double Blind Study of Hypertonic Saline vs Mannitol in the Management of Increased Intracranial Pressure (ICP).</brief_title>
  <official_title>Double Blind Study of Hypertonic Saline vs Mannitol in the Management of Increased Intracranial Pressure (ICP).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study goal is to compare the management of increased intra-cranial pressure (ICP) using
      3% hypertonic saline vs. mannitol (given in same osmolar loads).

      Primary hypothesis:

      1. Hypertonic saline will be non-inferior to mannitol in decreasing elevated ICP.

      Secondary hypotheses:

        1. Hypertonic saline therapy will result with fewer complications than mannitol

        2. ICP reduction duration will be longer using hypertonic saline when compared with
           mannitol
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is growing evidence in the literature indicating that ICP and Cerebral Perfusion
      Pressure measurements may not be sufficient in the management of elevated ICP. Based on this
      evidence, monitoring of partial brain tissue oxygenation has gain acceptance among
      neurosurgeons and neurointensivists, and has become a standard of care monitor in some
      centers across the country. There is, however, insufficient information in the literature
      describing the effects of hyperosmolar medications on regional brain tissue oxygenation.

      We intend to undertake this non-inferiority, prospective, randomized double-blind study to
      answer very important clinical questions not yet answered in the literature: Will hypertonic
      saline therapy, given at equiosmolar load, be non-inferior to mannitol in reducing elevated
      ICP?
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Timeline to consent prior to intervention start was unfeasible.
  </why_stopped>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent reduction of ICP from baseline</measure>
    <time_frame>30 minutes from completion of medication administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from study drug administration completion to ICP &lt; 25 mmHg</measure>
    <time_frame>First 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration of ICP below 25 mmHg</measure>
    <time_frame>First 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration of ICP below 25 mmHg</measure>
    <time_frame>First 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration of cerebral perfusion pressure (CPP) above 60 mmHg</measure>
    <time_frame>First 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration of cerebral perfusion pressure (CPP) above 60 mmHg</measure>
    <time_frame>First 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration of regional oxygen partial pressure (pbtO2) &gt; 20%</measure>
    <time_frame>two hours following each dose administration during the first 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of medications given</measure>
    <time_frame>First 24 hours; also over 3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of treatment failure</measure>
    <time_frame>First 72 hours</time_frame>
    <description>Treatment failure defined as ICP &gt; 30 mmHg for &gt; 30 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of rebound intracranial hypertension</measure>
    <time_frame>First 72 hours</time_frame>
    <description>Rebound intracranial hypertension defined as ICP &gt; 25 mmHg for more than 10 minutes following ICP stabilization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of composite Major Adverse Events</measure>
    <time_frame>3 days</time_frame>
    <description>acute kidney injury as defined by an increase in creatinine x 2 or GFR decrease &gt; 50% or urine output &lt; 0.5 ml/kg/h for 12 hours, compared to baseline, as per RIFLE criteria
hypotensive episodes (SBP &lt; 90 mmHg for more than 10 minutes)
hemodynamic instability as measured by decrease of cardiac output by more than 15% within two hours following medication administration
pulmonary edema as defined by ELWI I&gt; 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in inflammatory response</measure>
    <time_frame>Regular intervals over first 3 days</time_frame>
    <description>Determined by analysis of cytokine and inflammatory biomarkers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in average pre-discharge stroke scale score</measure>
    <time_frame>hospital discharge (or 30 days if not discharged)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Elevated Intracranial Pressure</condition>
  <arm_group>
    <arm_group_label>hypertonic saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3% hypertonic saline, dosed by ideal patient weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mannitol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20% mannitol, dosed by patient's ideal body weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hypertonic saline</intervention_name>
    <description>3% hypertonic saline, dosed by ideal patient weight</description>
    <arm_group_label>hypertonic saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mannitol</intervention_name>
    <description>Mannitol 20% intravenous solution, dosed by patient's ideal body weight</description>
    <arm_group_label>Mannitol</arm_group_label>
    <other_name>Osmitrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  elevated ICP requiring ICP monitoring

          -  ICP ≥ 25 mmHg 5 min after ICP bolt or EVD placement

        Exclusion Criteria:

          -  Requiring decompressive craniotomy or post decompressive craniotomy

          -  Hyponatremia (sodium level &lt; 125 mEq/L)

          -  Hypernatremia (sodium &gt; 155 mmol/L)

          -  Serum osmolality ≤ 250 mOsm/kg

          -  Serum osmolality ≥ 320 mOsm/kg

          -  Physical exam compatible with brain death

          -  Patients on hemodialysis with end-stage renal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Achikam Oren-Grinberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shackford SR, Bourguignon PR, Wald SL, Rogers FB, Osler TM, Clark DE. Hypertonic saline resuscitation of patients with head injury: a prospective, randomized clinical trial. J Trauma. 1998 Jan;44(1):50-8.</citation>
    <PMID>9464749</PMID>
  </reference>
  <reference>
    <citation>BARRY KG, BERMAN AR. Mannitol infusion. III. The acute effect of the intravenous infusion of mannitol on blood and plasma volumes. N Engl J Med. 1961 May 25;264:1085-8.</citation>
    <PMID>13687351</PMID>
  </reference>
  <reference>
    <citation>Brain Trauma Foundation; American Association of Neurological Surgeons; Congress of Neurological Surgeons; Joint Section on Neurotrauma and Critical Care, AANS/CNS, Bratton SL, Chestnut RM, Ghajar J, McConnell Hammond FF, Harris OA, Hartl R, Manley GT, Nemecek A, Newell DW, Rosenthal G, Schouten J, Shutter L, Timmons SD, Ullman JS, Videtta W, Wilberger JE, Wright DW. Guidelines for the management of severe traumatic brain injury. II. Hyperosmolar therapy. J Neurotrauma. 2007;24 Suppl 1:S14-20. Erratum in: J Neurotrauma. 2008 Mar;25(3):276-8. multiple author names added.</citation>
    <PMID>17511539</PMID>
  </reference>
  <reference>
    <citation>The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care. Use of mannitol. J Neurotrauma. 2000 Jun-Jul;17(6-7):521-5. Review.</citation>
    <PMID>10937895</PMID>
  </reference>
  <reference>
    <citation>Bereczki D, Liu M, Prado GF, Fekete I. Cochrane report: A systematic review of mannitol therapy for acute ischemic stroke and cerebral parenchymal hemorrhage. Stroke. 2000 Nov;31(11):2719-22. Review.</citation>
    <PMID>11062300</PMID>
  </reference>
  <reference>
    <citation>Qureshi AI, Suarez JI, Bhardwaj A, Mirski M, Schnitzer MS, Hanley DF, Ulatowski JA. Use of hypertonic (3%) saline/acetate infusion in the treatment of cerebral edema: Effect on intracranial pressure and lateral displacement of the brain. Crit Care Med. 1998 Mar;26(3):440-6.</citation>
    <PMID>9504569</PMID>
  </reference>
  <reference>
    <citation>Huang SJ, Chang L, Han YY, Lee YC, Tu YK. Efficacy and safety of hypertonic saline solutions in the treatment of severe head injury. Surg Neurol. 2006 Jun;65(6):539-46; discussion 546.</citation>
    <PMID>16720165</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2010</study_first_submitted>
  <study_first_submitted_qc>April 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2010</study_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Achikam Orin-Grinberg</investigator_full_name>
    <investigator_title>Assistant Professor of Anaesthesia</investigator_title>
  </responsible_party>
  <keyword>clinical trial</keyword>
  <keyword>mannitol</keyword>
  <keyword>intracranial pressure (ICP)</keyword>
  <keyword>hypertonic saline</keyword>
  <keyword>cerebral edema</keyword>
  <keyword>traumatic brain injury (TBI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

